Taken together, the observed anti-obesity effects of KRGM-gintonin via both oral and central administration routes may, at least in part, be attributed to its enrichment of lipid components, especially LPA, a potent ligand for G protein-coupled LPA receptors (LPA1–6), which regulates diverse physiological processes, including adipogenesis, thermogenesis, and energy metabolism. The gene discussed is LPAR1; the disease is obesity due to melanocortin 4 receptor deficiency.